Open Government Licence

Companies developing new technologies to make medicines, including personalised treatments made at or near hospitals and clinics, manufacturing in space, and the use of AI, robotics and automation, are set to receive earlier practical support from the Medicines and Healthcare products Regulatory Agency (MHRA) to help promising technologies reach patients sooner.

The MHRA has secured funding from the Office for Life Sciences (OLS) to develop and test AdvanceGxP, announced by Science, Innovation and Investment Minister Chris McDonald MP in his closing speech at the inaugural DIA-MHRA Global Summit in London yesterday (17 November) as part of London Life Sciences Week.

Initially focusing on advanced manufacturing technologies, AdvanceGxP is being developed by the MHRA to help innovators address regulatory and quality questions earlier, reducing the risk of avoidable redesign and delays, and supporting more sustainable approaches.

The approach is intended to support patient access to new treatments and strengthen UK manufacturing, supporting the Government’s Life Sciences Sector Plan and wider Industrial Strategy.

Science, Innovation and Investment Minister, Chris McDonald MP, said:

“The UK is already a leader in life sciences research and, as new technologies enable rapid breakthroughs, we want to make sure that new treatments get to patients as soon as possible.

“AdvanceGxP will help innovators navigate regulation more smoothly, preventing delays and ensuring that patients get to see the benefits scientific advances as soon as possible.”

MHRA Chief Executive, Lawrence Tallon, said:

“We want the UK to be a place where the next generation of innovative medicines can be developed and made. Giving developers practical support earlier can help solve problems before they cause delays, build confidence to invest and make it easier for promising new approaches to grow and scale here.

“Ultimately, this is about creating the right environment for promising new approaches to become a reality and helping innovative treatments reach patients sooner.”

OLS Director, Kenan Poleo, said:

“As competition for life sciences investment intensifies, the UK’s regulatory environment can be a powerful competitive advantage. By helping regulation keep pace with innovation, AdvanceGxP will give companies greater confidence to develop and manufacture transformative new technologies here in the UK.”

New technologies are changing how and where medicines are made, from personalised treatments made at or near hospitals and clinics to manufacturing in space and the use of AI, robotics and automation. These advances can create questions about how established Good Practice standards for medicines manufacturing apply. AdvanceGxP will offer developers earlier access to specialist expertise to address these questions, helping avoid preventable redesign and delays later in development.

The funding will enable the MHRA to recruit a new specialist team and develop the service, including how organisations will access it, which technologies and projects will be prioritised, and how it will connect with existing MHRA support.

Initial capacity will be limited while the approach is developed and tested, with this work to inform how the service could operate sustainably and potentially broaden in the future.

AdvanceGxP will sit alongside wider MHRA work to give innovators earlier, more joined-up support for advanced manufacturing, helping create the conditions for promising ideas to be developed and manufactured in the UK and reach patients sooner.

This direction is reflected in the recently launched MHRA Strategy to 2030, which sets out a greater focus on early engagement and working across the health and life sciences system to support innovation, growth and patient access, and wider government ambitions to strengthen life sciences and advanced manufacturing in the UK.

This announcement was made at the inaugural DIA–MHRA Global Summit. Hosted jointly by the MHRA and the Drug Information Association (DIA), the Summit brings together international regulators, industry leaders, researchers, healthcare professionals and patient representatives to explore how global collaboration can support innovation.

Notes to editors

  1. To find out more, view the AdvanceGxP service page.
  2. The DIA-MHRA Global Summit, where this announcement was made, is part of London Life Sciences Week, a concentrated demonstration of the UK’s life sciences offer, and MHRA is proud to have a key role in connecting science, regulation, investment and patient benefit. Across key areas of focus this week – including women’s health, clinical research, AI, manufacturing, advanced therapeutics, and rare disease – better regulation means better evidence, clearer routes for innovators and greater potential for patient benefit.
  3. The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe. All our work is underpinned by robust and fact-based judgements to ensure that the benefits justify any risks.
  4. The MHRA is an executive agency of the Department of Health and Social Care.
  5. For media enquiries, please contact the [email protected], or call on 020 3080 7651.

To find out more, view the AdvanceGxP service page.

The DIA-MHRA Global Summit, where this announcement was made, is part of London Life Sciences Week, a concentrated demonstration of the UK’s life sciences offer, and MHRA is proud to have a key role in connecting science, regulation, investment and patient benefit. Across key areas of focus this week – including women’s health, clinical research, AI, manufacturing, advanced therapeutics, and rare disease – better regulation means better evidence, clearer routes for innovators and greater potential for patient benefit.

The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe. All our work is underpinned by robust and fact-based judgements to ensure that the benefits justify any risks.

The MHRA is an executive agency of the Department of Health and Social Care.

For media enquiries, please contact the [email protected], or call on 020 3080 7651.